Role of tissue factor pathway inhibitor in post surgical deep venous thrombosis (DVT) prophylaxis in patients treated with low molecular weight heparin
- 1 April 1994
- journal article
- Published by Elsevier in Thrombosis Research
- Vol. 74 (1) , 53-64
- https://doi.org/10.1016/0049-3848(94)90035-3
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgeryThe Lancet, 1993
- Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediatorsBlood, 1992
- Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: synergistic anticoagulant action between LACI and sulfated polysaccharidesBlood, 1992
- Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samplesBlood, 1991
- Purification and properties of heparin-releasable lipoprotein- associated coagulation inhibitorBlood, 1991
- Prevention of Deep Vein Thrombosis after Elective Hip SurgeryAnnals of Internal Medicine, 1991
- Heparin induces release of extrinsic: Coagulation pathway inhibitor (EPI)Thrombosis Research, 1988
- The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of actionBlood, 1988
- Effect of Heparin and Heparin Fractions on Platelet AggregationJournal of Clinical Investigation, 1980